1.Sensory Processing Disorders are Associated with Duration of Current Episode and Severity of Side Effects.
Gianluca SERAFINI ; Batya ENGEL-YEGER ; Gustavo H VAZQUEZ ; Maurizio POMPILI ; Mario AMORE
Psychiatry Investigation 2017;14(1):51-57
OBJECTIVE: Longer duration of untreated illness, longer duration of current episode, and the severity of medication side effects may negatively impact on the perceived disability and psychosocial impairment of patients with major affective and anxiety disorders. Studies also suggested the involvement of sensory perception in emotional and psychopathological processes. The present study aimed to examine the relationship between Sensory Processing Disorders (SPD), duration of untreated illness and current illness episode, and the severity of side effects related to psychoactive medications. METHODS: The sample included 178 participants with an age ranging from 17 to 85 years (mean=53.84±15.55). Participants were diagnosed with unipolar Major Depressive Disorder (MDD) (50%), Bipolar Disorder (BD) (33.7%), and Anxiety disorders (16.3%). They completed a socio-demographic questionnaire, the Udvalg for Kliniske Undersøgelser (UKU), and Adolescent/Adult Sensory Profile (AASP) questionnaire. RESULTS: Longer duration of current episode correlated with greater registration of sensory input and lower avoidance from sensory input among unipolar patients; with lower registration of sensory input, and higher tendency for sensory sensitivity/avoidance among bipolar participants; with lower sensory sensitivity/avoidance among anxiety participants, respectively. Also, mean UKU total scores correlated with lower sensory sensitivity among bipolar individuals. CONCLUSION: SPD expressed in either hypo/hyper sensitivity may serve to clinically characterize subjects with major affective and anxiety disorders.
Anxiety
;
Anxiety Disorders
;
Bipolar Disorder
;
Depressive Disorder, Major
;
Humans
;
Hypersensitivity
2.Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the “Real World” Clinical Practice
Domenico DE BERARDIS ; Luigi OLIVIERI ; Gabriella RAPINI ; Serena DI NATALE ; Nicola SERRONI ; Michele FORNARO ; Laura ORSOLINI ; Alessandro VALCHERA ; Alessandro CARANO ; Federica VELLANTE ; Paola Annunziata VARASANO ; Gabriella Lucidi PRESSANTI ; Gianluca SERAFINI ; Maurizio POMPILI ; Giovanni MARTINOTTI ; Massimo DI GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2019;17(2):318-322
OBJECTIVE: This study was performed to elucidate relationships between alexithymia, suicide ideation and homocysteine levels in drug-naïve outpatients with major depressive disorder (MDD). METHODS: Sixty seven outpatients with MDD with melancholic features were evaluated by the means of the Hamilton Depression Rating Scale, the Toronto Alexithymia Scale (TAS–20), the Scale of Suicide Ideation, and homocysteine levels. RESULTS: Alexithymic subjects showed higher scores on all scales and higher homocysteine levels. Regression analysis shown higher homocysteine levels and TAS-20’ “Difficulty in Describing Feelings” dimension, in turn being associated with higher suicide ideation. CONCLUSION: In conclusion, alexithymic MDD outpatients may characterize for homocysteine dysregulation that may be linked to suicide ideation, regardless depression’ severity. However, study limitations are discussed and must be considered.
Affective Symptoms
;
Depression
;
Depressive Disorder, Major
;
Homocysteine
;
Humans
;
Outpatients
;
Suicidal Ideation
;
Suicide
;
Weights and Measures
3.Understanding the Complex of Suicide in Depression: from Research to Clinics
Laura ORSOLINI ; Roberto LATINI ; Maurizio POMPILI ; Gianluca SERAFINI ; Umberto VOLPE ; Federica VELLANTE ; Michele FORNARO ; Alessandro VALCHERA ; Carmine TOMASETTI ; Silvia FRATICELLI ; Marco ALESSANDRINI ; Raffaella LA ROVERE ; Sabatino TROTTA ; Giovanni MARTINOTTI ; Massimo DI GIANNANTONIO ; Domenico DE BERARDIS
Psychiatry Investigation 2020;17(3):207-221
Objective:
Amongst psychiatric disorders, major depressive disorder (MDD) is the most prevalent, by affecting approximately 15–17% of the population and showing a high suicide risk rate equivalent to around 15%. The present comprehensive overview aims at evaluating main research studies in the field of MDD at suicide risk, by proposing as well as a schematic suicide risk stratification and useful flow-chart for planning suicide preventive and therapeutic interventions for clinicians.
Methods:
A broad and comprehensive overview has been here conducted by using PubMed/Medline, combining the search strategy of free text terms and exploded MESH headings for the topics of ‘Major Depressive Disorder’ and ‘Suicide’ as following: ((suicide [Title/Abstract]) AND (major depressive disorder [Title/Abstract])). All articles published in English through May 31, 2019 were summarized in a comprehensive way.
Results:
Despite possible pathophysiological factors which may explain the complexity of suicide in MDD, scientific evidence supposed the synergic role of genetics, exogenous and endogenous stressors (i.e., interpersonal, professional, financial, as well as psychiatric disorders), epigenetic, the hypothalamic-pituitary-adrenal stress-response system, the involvement of the monoaminergic neurotransmitter systems, particularly the serotonergic ones, the lipid profile, neuro-immunological biomarkers, the Brain-derived neurotrophic factor and other neuromodulators.
Conclusion
The present overview reported that suicide is a highly complex and multifaceted phenomenon in which a large plethora of mechanisms could be variable implicated, particularly amongst MDD subjects. Beyond these consideration, modern psychiatry needs a better interpretation of suicide risk with a more careful assessment of suicide risk stratification and planning of clinical and treatment interventions.
4.High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
Adriano PELLICELLI ; Vincenzo MESSINA ; Valerio GIANNELLI ; Marco DISTEFANO ; Valeria Pace PALITTI ; Pascal VIGNALLY ; Pierluigi TARQUINI ; Antonio IZZI ; Alessandra MORETTI ; Sergio BABUDIERI ; Serena DELL’ISOLA ; Massimo MARIGNANI ; Gaetano SCIFO ; Vincenzo IOVINELLA ; Giuseppe CARITI ; Maurizio POMPILI ; Francesco Di CANDILO ; Luca FONTANELLA ; Giuseppe M. ETTORRE ; Giovanni VENNARECCI ; Antonio Massimo IPPOLITO ; Giorgio BARBARINI
Gut and Liver 2020;14(3):357-367
Background/Aims:
Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir (DCV)/sofosbuvir (SOF) plus a flat dose of 800 mg RBV (flat dose) compared to DCV/SOF without RBV or DCV/SOF plus an RBV dose based on body weight (weight-based) in G3-HCV patients with compensated or decompensated cirrhosis.
Methods:
We analyzed data for 233 G3 cirrhotic patients. Of these, 70 (30%), 87(37%) and 76 (33%) received SOF/DCV, SOF/DCV/RBV flat dose, and SOF/DCV/RBV weight-based dose, respectively. Treatment duration was 24 weeks. Sustained virological response (SVR) was evaluated at week 12 posttreatment (SVR12).
Results:
Overall, SVR12 was achieved in 220 out of 233 patients (94.4%). The SVR12 rate was lower in the DCV/SOF group than in the DCV/SOF/RBV flat-dose group and the DCV/SOF/RBV weight-based group (87.1% vs 97.7% and 97.4%, respectively, p=0.007). A higher incidence of anemia occurred in the DCV/SOF/RBV weight-based group compared to those in the other two groups (p<0.007).
Conclusions
We found that the DCV/SOF/RBV flat-dose regimen is an effective treatment in terms of efficacy and safety in patients with G3-HCV compensated or decompensated cirrhosis. Therefore, antiviral regimens without RBV should be restricted only to naïve patients with G3-HCV compensated cirrhosis who have a clear contraindication for RBV.